Improving the diagnosis
and treatment of
cancer and other diseases

So your online presence really delivers at each step

Learn more

INOVIQ has a multi-product pipeline for detection and monitoring of breast, ovarian and other cancers

So your online presence really delivers at each step

Learn more

Innovative solutions using proprietary SubB2M™, NETs, BARD1 and hTERT technologies

So your online presence really delivers at each step

Learn more

Who we are

INOVIQ Ltd (ASX:IIQ) is developing and commercialising a portfolio of diagnostic and exosome-based products for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases.

Who we are

INOVIQ Ltd (ASX:IIQ) is developing and commercialising a portfolio of diagnostic and exosome-based products for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases.

Our Technologies

INOVIQ owns or licences the proprietary SubB2M™, NETs, BARD1 and hTERT technologies that have multiple potential diagnostic and therapeutic applications.

Our Products

INOVIQ has commercialised two products including the hTERT test for use as an adjunct to urine cytology testing for bladder cancer and the EXO-NET® pan-exosome capture tool for research purposes.

Pipeline

INOVIQ is developing a multi-product diagnostic and exosome-based pipeline focused on the detection and monitoring of cancer and other diseases to improve patient health outcomes.

Recent News

...

Latest Presentation

...

Share Price

ASX:
Subscribe To
Email Alerts